HOME > BUSINESS
BUSINESS
- Takeda Files NDA in Japan for Cetilistat for Treatment of Obesity
October 31, 2012
- Mitsubishi Tanabe Reports Growth in 1st-Half Sales with Boost from Remicade, Telavic
October 31, 2012
- Kyowa Hakko Bio to Set Up New Plant in Thailand in Response to Rising Demand for Amino Acids
October 30, 2012
- Equity Participation in ViiV Hoped to Cover Patent Loss of Crestor: Shionogi Pres. Teshirogi
October 30, 2012
- Major Japanese Drug Makers Strengthen Vaccine Business, Eyeing Global Operations
October 30, 2012
- Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
- DSP, Takeda Submit Application for Antipsychotic Lurasidone in Europe
October 30, 2012
- Nihon Chouzai to Make Choseido its Subsidiary to Strengthen Generic Products Supply Capacity
October 30, 2012
- Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
- Kyowa Kirin: Pharmaceutical Sales Up 8.4%, but Domestic Sales Down in January to September Period
October 29, 2012
- Nippon Chemiphar Revises 1st Half Business Forecast Upward, Full Year Forecast Unchanged
October 29, 2012
- MTPC to Launch Quadruple Vaccine TETRABIK on October 31 with 50 Vaccine Specialized MRs
October 29, 2012
- Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
- Everlth President Hasegawa Sends Out Information to World on Activities of Pharmaceutical Wholesalers at Time of Great East Japan Earthquake
October 26, 2012
- Takeda Starts Detailing Activities through M3’s “Tenohira MR-kun” on iPads
October 26, 2012
- AnGes MG Inks Definitive Deal to Grant Exclusive US Marketing Rights for Collategene to MTPC
October 25, 2012
- Kyowa Kirin to Construct Biopharmaceutical API Manufacturing Facility
October 25, 2012
- Ono Ties Up with Domain Therapeutics of France for GPCR-Based Drug Discovery
October 25, 2012
- ZOLL Medical Acquired by Asahi Kasei Last Year Establishes Japanese Subsidiary
October 25, 2012
- Fujifilm, Kyowa Kirin to Develop Avastin Biosimilar
October 25, 2012
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
